Stable Therapeutic Transgenic FIX Levels for More Than 10 Years in Subjects with Severe Hemophilia B Who Received scAAV2/8-LP1-Hfixco Adeno-Associated Virus Gene Therapy
Reiss U, Davidoff A, Tuddenham E, Chowdary P, McIntosh J, Riddell A, Pie A, Batty P, Calvert J, Mangles S, Mahlangu J, Haley K, Recht M, Shen Y, Halka K, Zhou J, Kang G, Okhomina V, Morton C, Nathwani A. Stable Therapeutic Transgenic FIX Levels for More Than 10 Years in Subjects with Severe Hemophilia B Who Received scAAV2/8-LP1-Hfixco Adeno-Associated Virus Gene Therapy. Blood 2023, 142: 1056. DOI: 10.1182/blood-2023-186891.Peer-Reviewed Original ResearchAnnualized bleeding rateSelf-complementary adeno-associated virusGene therapySevere hemophilia BFactor IXFactor IX activityAdverse eventsHemophilia BAdeno-associated virus gene therapyFollow-upTransient elevation of liver transaminasesLung adenocarcinoma in situMedian annualized bleeding rateElevation of liver transaminasesTreatment-related adverse eventsHigh vector dosesYears of follow-upSustained clinical benefitMedian Follow-UpAdenocarcinoma in situAdeno-associated virusFactor IX inhibitorsFirst-in-humanLiver-specific promoterDose-dependent increase
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply